**Abstract**

**Background:** OCD has a strong genetic component, is highly comorbid with MDD, and is often triggered by stress. Genetic and epigenetic variation in *SKA2* has been implicated in mediating stress response, and has recently been associated with suicidal behavior in MDD (Kaminsky, 2014). The *SKA2* polymorphism rs7208505 exhibits allele-specific methylation. We hypothesized that genetic and epigenetic variation at *SKA2* may play a role in OCD disease risk and severity.

**Methods:** A sample of n=64 OCD patients, divided equally by presence/absence of comorbid MDD, and age and gender matched, were selected. Y-BOCS score was used to measure disease severity. Genotypes for rs7208505 were compared to Caucasian controls (n=379, 1000 Genomes Project) using Fisher's Exact test. The relationship among the rs7208505 variant, OCD disease severity, and MDD status was analyzed using ANCOVA. DNA methylation levels were quantified using bisulfite pyrosequencing. Pearson's r was used to investigate the correlation between percentage methylation and OCD symptom severity.

**Results:** The *SKA2* rs7208505 genotypes significantly differed between OCD patients and controls (χ^2^=10.21, p=0.006). The CC genotype was significantly associated with lower symptom severity than the CT/TT genotypes (F(3,52)=4.709, p=0.006). Percent methylation was negatively correlated with OCD severity (r=-0.438, n=56, p=0.001). Neither genetic nor epigenetic variation of rs7208505 was associated with comorbid MDD status.

**Conclusions:** These results provide some evidence that *SKA2* genetic and epigenetic variation may be a predictor of OCD risk and severity, regardless of MDD comorbidity; however, replication in larger samples is required. Further work will include interrogating additional genetic and epigenetic variations in *SKA2*.
